Continuous glucose monitoring pilot in low-income type 1 diabetes patients.

abstract：BACKGROUND:Automated insulin management features of the MiniMed® 640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery up...

journal_title：Diabetes technology & therapeutics

authors： Zhong A,Choudhary P,McMahon C,Agrawal P,Welsh JB,Cordero TL,Kaufman FR

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Proper healing of ulcers and wounds on the feet of diabetes patients is important in order to prevent amputation. If the wound area reduction during the first 4 weeks of the treatment is not 40% or more, reevaluation of the treatment is necessary. The wound area evaluation is not complicated when the patient...

journal_title：Diabetes technology & therapeutics

authors： Foltynski P,Ladyzynski P,Migalska-Musial K,Sabalinska S,Ciechanowska A,Wojcicki J

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:Diabetes mellitus is rare in young infants and neonates. Continuous subcutaneous insulin infusion (CSII) is used most frequently for insulin treatment in this age group. However, the individual doctor's experience is scarce because of the low prevalence of diabetes in this age. For this study patients treate...

journal_title：Diabetes technology & therapeutics

authors： Kapellen TM,Heidtmann B,Lilienthal E,Rami-Merhar B,Engler-Schmidt C,Holl RW

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Continuous subcutaneous insulin infusion (CSII) is an effective method of insulin substitution with increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in rare situations. The lack of subcutaneous long-acting insulin and short half-life of serum insulin increases the risk of ketosis and DKA follow...

journal_title：Diabetes technology & therapeutics

authors： Alemzadeh R,Parton EA,Holzum MK

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:Weight gain often occurs when insulin therapy is initiated. The long-acting insulin analog insulin detemir has been shown to be effective and well tolerated when used in basal-bolus regimens or as an add-on to oral antidiabetic drugs (OADs) and causes less weight gain than other insulins. The aim of this exp...

journal_title：Diabetes technology & therapeutics

authors： Davies MJ,Derezinski T,Pedersen CB,Clauson P

更新日期：2008-08-01 00:00:00

abstract：:New glucose sensors based on various technologies are being developed to provide information for improved therapy in diabetes. There is a need to establish rational performance standards for these sensors. Frequently sampled, direct blood glucose recordings representative of blood glucose excursions in diabetes are th...

journal_title：Diabetes technology & therapeutics

authors： Bremer TM,Edelman SV,Gough DA

更新日期：2001-10-01 00:00:00

abstract：:There is a clear role for inflammation in the development of type 2 diabetes and its associated co-morbidities. Circulating inflammatory markers such as C-reactive protein, sialic acid, and interleukin- 6 are all significant independent predictors of disease. A number of nutritional components are hypothesized to modu...

journal_title：Diabetes technology & therapeutics

authors： Browning LM,Jebb SA

更新日期：2006-02-01 00:00:00

abstract：BACKGROUND:There is no consensus as to the best method to assess glycemic variability from continuous glucose monitoring (CGM) data. Rate of change has been suggested as a preferred method of assessing glycemic variability, but this assertion has not been validated. METHODS:Forty-eight hours of CGM data were analyzed ...

journal_title：Diabetes technology & therapeutics

authors： Whitelaw BC,Choudhary P,Hopkins D

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS:PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy and safety of the implantable...

journal_title：Diabetes technology & therapeutics

authors： Christiansen MP,Klaff LJ,Brazg R,Chang AR,Levy CJ,Lam D,Denham DS,Atiee G,Bode BW,Walters SJ,Kelley L,Bailey TS

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) and sensor-augmented pump (SAP) therapy improve glucose control provided good adherence. In France, not only diabetologists, nurses, and dieticians but also nurses employed by homecare providers (HCPNs) are together involved in the initiation and/or follow-up of continuous...

journal_title：Diabetes technology & therapeutics

authors： Picard S,Hanaire H,Baillot-Rudoni S,Gilbert-Bonnemaison E,Not D,Reznik Y,Guerci B

更新日期：2016-03-01 00:00:00

abstract：BACKGROUND:The hyperinsulinemic euglycemic clamp is the gold standard for assessment of insulin resistance and requires frequent, accurate measurements of blood glucose concentrations, typically utilizing the YSI 2300 STAT Plus™ glucose analyzer (YSI, Inc., Yellow Springs, OH). Despite its accuracy, the YSI has several...

journal_title：Diabetes technology & therapeutics

authors： Lindquist KA,Chow K,West A,Pyle L,Isbell TS,Cree-Green M,Nadeau KJ

更新日期：2014-05-01 00:00:00

abstract：BACKGROUND:For patients with diabetes, the quality of outpatient glycemic control is readily assessed by hemoglobin A1c. In contrast, standardized measures for assessing the quality of blood glucose (BG) management in hospitalized patients are lacking. Because of recent studies demonstrating the benefits of strict glyc...

journal_title：Diabetes technology & therapeutics

authors： Goldberg PA,Bozzo JE,Thomas PG,Mesmer MM,Sakharova OV,Radford MJ,Inzucchi SE

更新日期：2006-10-01 00:00:00

abstract：BACKGROUND:For patients with type 1 diabetes mellitus, a bihormonal artificial endocrine pancreas system utilizing glucagon and insulin has been found to stabilize glycemic control. However, commercially available formulations of glucagon cannot currently be used in such systems because of physical instability characte...

journal_title：Diabetes technology & therapeutics

authors： Caputo N,Jackson MA,Castle JR,El Youssef J,Bakhtiani PA,Bergstrom CP,Carroll JM,Breen ME,Leonard GL,David LL,Roberts CT Jr,Ward WK

更新日期：2014-11-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) provides glucose trend information that can be used to guide treatment and motivate patients with diabetes. Currently, the evidence on effectiveness of CGM in patients with type 2 diabetes is debatable. We aim to provide a systematic review and meta-analysis to synthesize ...

journal_title：Diabetes technology & therapeutics

authors： Park C,Le QA

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Currently, it is still unknown whether differences in glycemic control have any effect on glucose and insulin kinetics after vildagliptin administration. The aim of this study was to evaluate the effect of vildagliptin on glucose and insulin concentrations during a 24-h period in type 2 diabetes patients wit...

journal_title：Diabetes technology & therapeutics

authors： González-Ortiz M,Sánchez-Peña MJ,González-Ortiz LJ,Robles-Cervantes JA,García-Ortega YE,Gómez-Gaitán EA,Pérez-Rubio KG,Martínez-Abundis E

更新日期：2013-07-01 00:00:00

abstract：:Although hypodermic needles rapidly deliver large doses of drugs such as insulin across the skin for systemic administration, the pain, local trauma, and difficulty to achieve sustained or complex delivery profiles has motivated development of novel alternative technologies. Microneedles, jet injectors, and thermal po...

journal_title：Diabetes technology & therapeutics

authors： Prausnitz MR

更新日期：2001-07-01 00:00:00

abstract：BACKGROUND:Preventing the complications of diabetes requires tight control and minimizing blood glucose fluctuation. Pursuing these goals increases the risk of severe hypoglycemia. The authors hoped to identify if using continuous glucose monitoring (CGM) decreased the incidence of severe hypoglycemia, resulted in less...

journal_title：Diabetes technology & therapeutics

authors： Halford J,Harris C

更新日期：2010-03-01 00:00:00

abstract：BACKGROUND:The value of self-monitoring of blood glucose (SMBG) for persons with type 2 diabetes who do not use insulin remains controversial. This observational study compares the likelihood of medication adherence and change in glycated hemoglobin (A1C) for non-insulin-using patients using SMBG versus those not using...

journal_title：Diabetes technology & therapeutics

authors： Virdi N,Daskiran M,Nigam S,Kozma C,Raja P

更新日期：2012-09-01 00:00:00

abstract：:Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have be...

journal_title：Diabetes technology & therapeutics

authors： Schnell O,Barnard K,Bergenstal R,Bosi E,Garg S,Guerci B,Haak T,Hirsch IB,Ji L,Joshi SR,Kamp M,Laffel L,Mathieu C,Polonsky WH,Snoek F,Home P

更新日期：2017-07-01 00:00:00

abstract：:Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

journal_title：Diabetes technology & therapeutics

authors： Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

更新日期：2012-11-01 00:00:00

abstract：: Background: Glycemic variability (GV) is an important component of glycemic control for patients with type 1 diabetes (T1D). The inadequacy of existing measurements lies in the fact that they view the variability from different aspects, so that no consensus has been reache...

journal_title：Diabetes technology & therapeutics

authors： Zheng F,Jalbert M,Forbes F,Bonnet S,Wojtusciszyn A,Lablanche S,Benhamou PY

更新日期：2020-04-01 00:00:00

abstract：AIMS:Skin autofluorescence (AF) has been associated with complications of diabetes. We evaluated the influence of skin color and ethnicity on the association between skin AF and the presence of diabetes-related complications. MATERIALS AND METHODS:In a multiethnic type 2 diabetes cohort we investigated all patients wi...

journal_title：Diabetes technology & therapeutics

authors： Ahdi M,Gerdes VE,Graaff R,Kuipers S,Smit AJ,Meesters EW

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:Vascular endothelial growth factor (VEGF) is involved in the pathogenesis of diabetic microvascular disease. Most diabetes patients have higher serum levels of ferritin that may participate in diabetic vascular complications through high oxidative stress induced by iron. However, the mechanistic link between...

journal_title：Diabetes technology & therapeutics

authors： Guo L,Jiang F,Tang YT,Si MY,Jiao XY

更新日期：2014-04-01 00:00:00

abstract：:Recent years have brought about an explosion in the number of companies offering connected diabetes care products, defined as digital diabetes management systems based around (1) smartphone apps, (2) devices with built-in connectivity, and (3) remote human and automated coaching and support. These nascent models aim t...

journal_title：Diabetes technology & therapeutics

authors： Levine BJ,Close KL,Gabbay RA

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform s...

journal_title：Diabetes technology & therapeutics

authors： Bergenstal RM,Bode BW,Tamler R,Trence DL,Stenger P,Schachner HC,Fullam J,Pardo S,Kohut T,Fisher WA

更新日期：2012-10-01 00:00:00

abstract：:Self-monitoring of blood glucose (SMBG) is universally considered to be an integral part of type 1 diabetes management and crucial for optimizing the safety and efficacy of complex insulin regimens. This extends to type 2 diabetes patients on intensive insulin therapy, and there is also a growing body of evidence sugg...

journal_title：Diabetes technology & therapeutics

authors： Czupryniak L,Barkai L,Bolgarska S,Bronisz A,Broz J,Cypryk K,Honka M,Janez A,Krnic M,Lalic N,Martinka E,Rahelic D,Roman G,Tankova T,Várkonyi T,Wolnik B,Zherdova N

更新日期：2014-07-01 00:00:00

abstract：BACKGROUND:The Optimizing Control in Diabetes (OPTIMIZE) survey was conducted to understand the patients' perspective to achieving good glycemic control and to determine how patients' perceptions of insulin may affect their decisions to initiate or intensify their insulin therapy. METHODS:A total of 1,444 subjects wit...

journal_title：Diabetes technology & therapeutics

authors： Cefalu WT,Mathieu C,Davidson J,Freemantle N,Gough S,Canovatchel W,OPTIMIZE Coalition.

更新日期：2008-02-01 00:00:00

abstract：:By the year 2030, the diabetes pandemic will likely affect more than 10% of the world's population. The personal, public health, and economic crises implicit in this trend call for decisive action. Yet, escalating dilemmas thwart full realization of current therapies. First, controversial studies, such as the Action t...

journal_title：Diabetes technology & therapeutics

authors： Hirsch IB,Amiel SA,Blumer IR,Bode BW,Edelman SV,Seley JJ,Verderese CA,Kilpatrick ES

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:A1chieve(®) (Novo Nordisk A/S, Bagsværd, Denmark) was a prospective, multicenter, noninterventional study in 66,726 people with type 2 diabetes mellitus (T2DM) in 28 countries beginning biphasic insulin aspart 30 (aspart premix), insulin detemir, or insulin aspart in routine clinical care. SUBJECTS AND METH...

journal_title：Diabetes technology & therapeutics

authors： Shah S,Yang W,Hasan MI,Malek R,Molskov Bech O,Home P

更新日期：2013-11-01 00:00:00

abstract：:It is widely accepted that noninvasive glucose monitoring (NIGM) has the potential to revolutionize diabetes therapy. However, current approaches to NIGM studied to date have not yet demonstrated a level of acceptable functionality to allow real-time use, beyond restricted fields of application. A number of reviews ha...

journal_title：Diabetes technology & therapeutics

authors： Caduff A,Talary MS,Zakharov P

更新日期：2010-01-01 00:00:00